Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation
BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cancer Conference but also many patients could be advised to avoid chemotherapy and radiotherapy altogether after assessing their risk as “low” by using a combination of clinical and genetic risk scores, the study concluded.
Emiel Rutgers MD, PhD, a surgeon at the Netherlands Cancer Institute and professor of surgical oncology at the University of Amsterdam said MINDACT found an overall five-year loco-regional recurrence rate of only 2.1 per cent in patients treated conservatively and 2.5 per cent in those who had mastectomy. Tumor size and grade were the only independent risk factors and the results provided “the opportunity to prospectively study de-escalation of radiotherapy in women with low-risk early breast cancer”. He discussed his study and the clinical implications for the Audio Journal of Oncology.
You may also like...
Geriatric Assessment Improved Outcomes for Older Patients with Cancer 11 Jul, 2018 
Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy 18 Dec, 2012 - Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies 26 Mar, 2014
Oncology Times Broadcast News with the Audio Journal of Oncology – Insulin-Like Growth Factor Inhibition In Lung Cancer 6 Apr, 2009
